Warner-lambert Company

Other

Mcneil-ppc, Inc.

William Bess

Neema Kulkarni

Leonard Mackles

Suhas H Ambike

Michael P Ramsay

W Michael Nichols

Albert F Sorg

Stanley Lech

George E Tortarolo

Victor A Cruz

William Michael Nichols

There is provided a new technology that will allow the formulation of pharmaceutically active organic acid products at relatively high pH during storage. This affords the advantages of avoiding formulation with the acid form of the product, yet when the product is used, the pH will be reduced via a chemical reaction, thus forming the organic acid which is the active form of the product. A by-product of the reaction is a significant increase in temperature, thus adding to the efficacy of the organic acid.

Low pH pharmacologically active products and methods for the production thereof

Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods for producing the films are also disclosed.

Fast dissolving orally consumable films containing a taste masking agent

There are provided oral mouth rinse compositions, consisting essentially of: a) 1&#x2013;20 wt % of an orally acceptable peroxide, b) 0.5&#x2013;15 wt % of an orally acceptable sulfate, bisulfate, pyrosulfate salt of an inorganic cation or mixtures thereof, and c) water to 100 wt %. There are further provided methods of preparing and using said compositions as well as kits for maintaining the components to prepare said compositions.

Mouth rinse with enhanced oxygenating activity

Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1

The instant invention makes impractical the use of sympathomimetic amine compositions in illicit drug production. More specifically, the preparation of methamphetamine from the disclosed pseudoephedrine hydrochloride formulations is inhibited. The present invention defines pharmaceutical compositions comprising a sympathomimetic amine salt and at least one combination inhibitor, the combination inhibitor which acts both to interfere with the isolation of the sympathomimetic amine from the composition and to interfere with the conversion of the sympathomimetic amine to another pharmacologically active compound. The contemplated compositions may also include reaction and separation inhibitors in any mixture to assure maximum protection against the use of the sympathomimetic amine-containing compositions for illegal drug manufacture. The presence of the combination, reaction and separation inhibitors does not significantly alter the release of the sympathomimetic amine from the composition.

Denaturants for sympathomimetic amine salts

The present invention is directed to pharmaceutical compositions containing triprolidine and an ionic additive that improves the measured availability of the triprolidine in the tablet, as indicated by standard USP assay for triprolidine in pharmaceutical compositions. The invention also provides a process for producing compositions having improved triprolidine availability and a process for improving the performance of a pharmaceutical composition in a dissolution assay measuring triprolidine availability. The ionic additive can be, for example, an alkali metal salt, such as sodium chloride or potassium chloride.

Dissolution of triprolidine hydrochloride

Growing community of inventors

Edison, NJ, United States of America

William Bess